

# EUROPEAN CURRICULUM VITAE



## PERSONAL DETAILS

I hereby authorize the treatment of my personal data in accordance with GDPR n. 679/16 and art. 13 Legislative Decree n. 96/03

Name	DOMENICA LORUSSO
Address	STRADA MALASPINA 10, PIOLTELLO (MI)
Telephone	+39 02 6951 6354
E-mail	<a href="mailto:domenica.lorusso@hunimed.eu">domenica.lorusso@hunimed.eu</a>

Nationality	Italy
Date of birth	March 09th, 1971 LRSDNC71C49E155Y

## WORK EXPERIENCE

• Dates (from – to)	<b>January 2024 - present</b>
• Name and address of employer	Humanitas San Pio X Hospital Via Francesco Nava, 31, 20159 Milano MI
• Occupation or position held	Head of Gynecologic Oncology Unit
• Dates (from – to)	<b>October 2023 - present</b>
• Name and address of employer	Humanitas University Via Rita Levi Montalcini, 4, 20072 Pieve Emanuele MI
• Type of business or sector	Gynecology and Obstetrics
• Occupation or position held	Full professor
• Dates (from – to)	<b>March 2020-December 2023</b>
• Name and address of employer	“Università Cattolica del Sacro Cuore” Largo Francesco Vito 1 00168 Rome, Italy
• Type of business or sector	“Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica”
• Occupation or position held	Associate Professor
• Dates (from – to)	<b>January 2019 – February 2020</b>
• Name and address of employer	“Fondazione Policlinico Universitario A Gemelli IRCCS” Largo Gemelli 8 00168 Rome, Italy
• Type of business or sector	Gynecologic Oncology Unit
• Occupation or position held	Associate Medical Director Head of “Unità Operativa Complessa” (UOC) of Clinical Research Development (since 2022) Head of “Unità Operativa Semplice Dipartimentale” (UOSD) of Clinical Research Development (from 2021 to 2022) Head of “Unità Operativa Semplice” (UOC) of Clinical Research Development (from 2019 to 2021)
• Main activities and responsibilities	MD

• Dates (from – to)	<b>May 2017 – December 2018</b>
• Name and address of employer	“Fondazione IRCCS Istituto Nazionale Tumori” Via G. Venezian 1, 20133 - Milano, Italy
• Type of business or sector	Gynecologic Oncology Unit
• Occupation or position held	Associate Medical Director, Responsible of Phase I Clinical Trials Unit for Gynecologic Oncology
• Main activities and responsibilities	MD
• Dates (from – to)	<b>July 2017 – December 2018</b>
• Name and address of employer	“Fondazione IRCCS Istituto Nazionale Tumori” Via G. Venezian 1, 20133 - Milano, Italy
• Type of business or sector	Gynecologic Oncology Unit
• Occupation or position held	Associate Medical Director, Head of Gynecological Medical Therapy Unit
• Main activities and responsibilities	MD
• Dates (from – to)	<b>November 2011 – December 2018</b>
• Name and address of employer	“Fondazione IRCCS Istituto Nazionale Tumori” Via G. Venezian 1, 20133 - Milano, Italy
• Type of business or sector	Gynecologic surgery Unit
• Occupation or position held	Associate Medical Director
• Main activities and responsibilities	MD, Responsible for the medical treatments of gynecological neoplasms and clinical trials
• Dates (from – to)	<b>May 2007 – October 2011</b>
• Name and address of employer	“Fondazione Policlinico Universitario A Gemelli IRCCS” Largo Gemelli 8 ,00168 Roma
• Type of business or sector	Gynecologic Oncology Unit - Dept. of ‘Tutela della salute della donna e della vita nascente’
• Occupation or position held	Associate Medical Director
• Main activities and responsibilities	MD, Responsible for the medical treatment of gynecological neoplasms and clinical trials
• Dates (from – to)	<b>September 2003 – April 2007</b>
• Name and address of employer	“Centro di Ricerca e Formazione ad Alta Tecnologia nelle Scienze Biomediche - Giovanni Paolo II” “Università Cattolica del Sacro Cuore” of Campobasso
• Type of business or sector	Gynecologic Oncology Unit
• Occupation or position held	Associate Medical Director
• Main activities and responsibilities	MD, Responsible for the medical treatment of gynecological neoplasms and clinical trials

#### ABILITAZIONI SCIENTIFICHE NAZIONALI

• Date	<b>09/07/2020</b>
• Field	<b>06/D3 <i>Malattie del sangue, Oncologia e Reumatologia</i> (I fascia)</b>
• Quarter	4°
• Date	<b>09/11/2018</b>
• Field	<b>06/H1 <i>Ginecologia e Ostetricia</i> (I fascia)</b>
• Quarter	5°
• Date	<b>31/10/2018</b>
• Field	<b>06/D3 <i>Malattie del sangue, Oncologia e Reumatologia</i> (II fascia)</b>
• Date	<b>02/01/2014</b>
• Field	<b>06/H1 <i>Ginecologia e Ostetricia</i> (II fascia)</b>

**EDUCATION AND TRAINING**

• Dates	<b>October 2003</b>
• Name and type of organisation providing education and training	MD Anderson Cancer Center – Houston Breast Unit
• Title of qualification awarded	Visiting physician
• Dates	<b>Jan 2003-Apr 2003</b>
• Name and type of organisation providing education and training	“San Giovanni” Hospital - Bellinzona (Switzerland) Clinical Trials Unit – Oncologic Department
• Title of qualification awarded	Visiting physician
• Dates	<b>2003</b>
• Name and type of organisation providing education and training	University of Parma
• Title of qualification awarded	PhD in Obstetrics and Gynecology
• Dates	<b>2000</b>
• Name and type of organisation providing education and training	Medical Schools of Rome
• Title of qualification awarded	Diploma of theoretical and practical course of hysteroscopy
• Dates	<b>1999</b>
• Name and type of organisation providing education and training	Medical Schools of Rome
• Title of qualification awarded	Diploma of the theoretical-practical course of colposcopy
• Dates	<b>1999</b>
• Name and type of organisation providing education and training	“Università Cattolica del Sacro Cuore” of Rome
• Title of qualification awarded	Second Level Degree in Obstetrics and Gynecology
• Level in national classification (if appropriate)	50/50 cum laude
• Name and type of organisation providing education and training	<b>1996</b>
• Title of qualification awarded	Enrollment in the professional order of physicians in Bari with number 11105
• Dates	<b>1995</b>
• Name and type of organisation providing education and training	“Università Cattolica del Sacro Cuore” of Rome
• Title of qualification awarded	First Level Degree in Medicine and Surgery
• Level in national classification (if appropriate)	110/110 cum laude
• Dates	<b>1992</b>
• Name and type of organisation providing education and training	University of Rome ‘Cattolica del Sacro Cuore’ Pathology Institute
• Title of qualification awarded	Fellowship
• Dates	<b>1989</b>
• Name and type of organisation providing education and training	State Scientific High School ‘G. Tarantino’, Gravina in Puglia, Italy
• Title of qualification awarded	Bachelor of Science
• Level in national classification (if appropriate)	60/60

<b>SKILLS AND COMPETENCES</b> <i>Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas</i>	<ul style="list-style-type: none"> <li>○ Experience in design, development and management of phase I-II-III-IV Clinical Trials, according to the Good Clinical Practices (GCP);</li> <li>○ GCP Training</li> <li>○ Advanced Life Support (ALS) training</li> </ul>
---	--

	<ul style="list-style-type: none"> <li>○ Principal Investigator in 108 Clinical Trials for pharmacological and surgical treatments of Gynecological Malignancies in the last 10 years; sub-investigators in several clinical trials from 2000 to 2012</li> <li>○ Well recognized Expertise at national and international level in the treatment of Gynecological Cancers</li> <li>○ Trained for Phase 1 trial conduction according to “Determina AIFA n. 809/2015 del 19 giugno 2015”</li> <li>● <u>Memberships:</u> <ul style="list-style-type: none"> <li>○ Italian Society of Germinal Tumors Treatment (since 2004)</li> <li>○ GCIG - Gynecological Cancer Intergroup (since 2005)</li> <li>○ ENGOT - European Network in Gynecologic Oncologic Trials (since 2009)</li> <li>○ Italian Society of Gynecologic Oncology (SIGO, since 2010)</li> <li>○ Scientific Board of ACTO Onlus (Alleanza contro il tumore dell'ovaio) (since 2012)</li> <li>○ AIOM – Italian Society of Medical Oncology (since 2013)</li> <li>○ ESMO - European Society of Medical Oncologic (Scientific Committee of Gynecological Cancer since 2014)</li> <li>○ ESGO - European Society of Gynecologic Oncology (since 2015)</li> <li>○ Rare Cancer Network for rare gynecological neoplasms (from 2012 to 2018)</li> <li>○ ERN (European Cancer Network) project. Responsible on behalf of INT Milano for rare gynecological neoplasms (from 2017 to 2018)</li> <li>○ Scientific Board of Salute Donna Onlus (since 2017)</li> <li>○ Scientific Board of aBRCAdaBRA Onlus (since 2019)</li> <li>○ Scientific Board of ONDA Foundation for Gynecological Cancer Treatment Center Accreditation (Bollino Rosa accreditation)</li> <li>○ Alleanza Contro il Cancro, representative delegate on behalf of Fondazione Policlinico Gemelli IRCCS (Since 2019)</li> <li>○ Scientific and Technical Committee (CTS) of “Fondazione Universitaria di Medicina molecolare e Terapia cellulare, Universita' di Ancona (since 2021) upon Minister of University assignment</li> <li>○ Scientific and Technical Committee (CTS) of Italian Association of Cancer Research (AIRC) (since 2022)</li> <li>○ Nominated member of “Cabina di regia commissione ministeriale per il rinnovo del Piano Nazionale Cronicità” (2022) (appointed by Minister of Health)</li> <li>○ Nominated member of “Commissione ministeriale per Educazione Continua in Medicina” (ECM) (2023) (appointed by Minister of Health)</li> <li>○ COST (European Cooperation in Science and Technology) Association (since 2023)</li> <li>○ Scientific and Technical Committee (CTS) of French National Cancer Institute Program for Hospital Clinical Research in Cancer (since 2023)</li> <li>○ Scientific and Technical Committee (CTS) of Lega Italiana per la Lotta ai Tumori (LILT) (since 2023)</li> </ul> </li> <li>● <u>Chairing positions:</u> <ul style="list-style-type: none"> <li>○ Board of Director of Multicenter Italian Ovarian Cancer Intergroup (MITO) (since 2004)</li> <li>○ Chair of Clinical trials Committee of MITO (from 2006 to 2017)</li> <li>○ Chair of Endometrial Cancer Committee of the Gynecological Cancer Intergroup (from 2012 to 2016)</li> <li>○ Board of Director of Gynecological Cancer Intergroup (GCIG) (since 2016)</li> <li>○ Board of Director and vice-president of Women for Oncology, Italy (since 2016)</li> <li>○ Scientific Track Chair of the Gynecological Cancer Program (ESMO 2017)</li> <li>○ Chair of Gynecologic Cancer Academy of European Network in Gynecologic Oncologic Trials (ENGOT) (since 2018, ongoing)</li> <li>○ Chair of the Commission for International networking for MITO (Multicenter Italian Ovarian Cancer) Intergroup (since 2018, ongoing)</li> <li>○ Scientific Chair of ESMO Summit Russia (2019)</li> <li>○ Chair of the SIGO working group on uterine sarcomas treatment (2017-2021)</li> <li>○ Chair of Nomination and Meeting Working Group of GCIG (2018-2021)</li> <li>○ Scientific Track Chair of Gynecological Cancer Program (ESMO Asia 2020-2022)</li> <li>○ Scientific Chair of ESMO Gynecological Cancer annual meeting (since 2020, ongoing)</li> </ul> </li> </ul>
--	--

	<ul style="list-style-type: none"> <li>○ Member of Board of Director of the European Society of Gynecologic Oncology (ESGO) Council, since 2022, ongoing)</li> <li>○ Scientific Chair of ESGO Annual Meetings 2023 and 2024</li> <li>○ Scientific Chair of ESGO course on Molecular Pathology and Targeted Therapy in Gynecological Cancers (2022)</li> <li>● <u>University Teaching for:</u> <ul style="list-style-type: none"> <li>○ "Vulvar Cancer" course at University of Foggia (2010)</li> <li>○ "Obstetrics and Gynecology course" at Istituto Nazionale Tumori of Milan (2013)</li> <li>○ Gynecological Cancer course to Medical Oncology fellow at University of Milan (from 2013 to 2017)</li> <li>○ Degree course in Nursing Sciences at the University of Milan (from 2012 to 2014)</li> <li>○ "Gynecological Cancer treatment" course at Master in Oncological Pharmacology (from 2015 to 2016)</li> <li>○ Obstetrics and Gynecology Course at Medicine and Surgery Faculty at Catholic University of Sacred Heart of Rome (from 2020 to 2023).</li> <li>○ Obstetrics and Gynecology Course at Obstetrics and Gynecology Residency of Catholic University of Sacred Heart of Rome (from 2020 to 2023)</li> <li>○ "Genomics in Gynecological Cancer" course at Medicine and Surgery Faculty of Catholic University of Sacred Heart (from 2020 to 2023)</li> <li>○ Obstetrics and Gynecology Course at Scuola Provinciale Superiore di Sanità - (University of Bolzano) (from 2022 to 2023);</li> <li>○ "From preclinical model to clinical rationale in the personalized therapy era" course at Catholic University of Sacred Heart of Rome (from 2010 to 2022)</li> <li>○ "Methodology of clinical research and clinical trial "course at II degree Master of Gynecologic Oncology at Catholic University of Sacred Heart (from 2017 to 2023)</li> <li>○ "Clinical trial in personalized Medicine in Gynecologic Oncology" course at Master of Big Data (2021-2023)</li> <li>○ Scientific Director of "Regolamentazione e gestione delle sperimentazioni cliniche" IIInd level course at Catholic University of Sacred Heart</li> <li>○ "Clinical Trials" Course at II degree Master of Minimally Invasive Gynecological Surgery at Catholic University of Sacred Heart from 2019 to 2022</li> <li>○ "Medical treatment of ovarian, endometrial, cervical cancer and uterine sarcoma" course at II degree Master of Gynecological Ultrasound at Catholic University of Sacred Heart from 2021 to 2023</li> </ul> </li> </ul>
	<p><u>Editorial board for:</u></p> <ul style="list-style-type: none"> <li>○ Website "Ovarian cancer Community" (editorial board) (from 2010 to 2012)</li> <li>○ Website "No nausea" (editorial board) (from 2013 to 2017)</li> <li>○ Cancer Breaking News (editorial board) (from 2014 to 2017)</li> <li>○ Annals of Oncology (editorial board) (since 2017)</li> <li>○ Gynecologic Oncology (editorial board) (since 2018)</li> <li>○ Tumori Journal (section editor and editorial board) (since 2016)</li> <li>○ International Journal of Gynecological Cancer (editorial board) (since 2018)</li> <li>○ Cells (section editor and editorial board) (since 2016) (since 2019)</li> </ul> <p><u>Peer review activity for scientific journals. The journals' list includes, but is not limited to:</u></p> <ul style="list-style-type: none"> <li>○ Lancet</li> <li>○ Lancet Oncology</li> <li>○ New England Journal of Medicin</li> <li>○ Jama Oncology</li> <li>○ Esmo Open</li> <li>○ Expert Opinion on Investigational drugs</li> <li>○ Critical Rev in Oncology and Haematology</li> <li>○ Future oncology</li> <li>○ Jama Oncology</li> <li>○ Journal of Clinical Oncology</li> <li>○ JCO Precision Oncology</li> </ul>

	<ul style="list-style-type: none"> <li>○ PLOS One</li> <li>○ Expert Opin Pharmacotherapy</li> <li>○ Oncology</li> <li>○ Cancer Treatment Review</li> <li>○ Supportive Care Cancer</li> <li>○ British Journal of Cancer</li> <li>○ Annals of surgical oncology</li> <li>○ Frontiers in Oncology</li> <li>○ Journal of Experimental and Clinical Cancer Research</li> <li>○ European Journal of Cancer</li> <li>○ Targeted Oncology</li> <li>○ Expert Opinion on Emerging Drugs</li> <li>○ European Journal of Surgical Oncology</li> <li>○ Vaccines</li> </ul> <p><b><u>Guidelines and consensus</u></b></p> <ul style="list-style-type: none"> <li>○ Co-author of the guidelines on the treatment of skin toxicity caused by PLD chemotherapy (PMID: 18331788)</li> <li>○ Co-authotr of national guidelines (AIOM) on treatment of uterine cancer (from 2014 to 2017)</li> <li>○ Co-author of the GCIG Consensus on the Treatment of Rare Gynecological Cancers (2015)</li> <li>○ Co-author of the V World Consensus Conference (GCIG) on the treatment of ovarian cancer - Tokyo November 2015</li> <li>○ Co-author of the ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up (2015).</li> <li>○ Co-author of "1st Evidence-based Italian consensus conference" sulla chirurgia citoriduttiva e chemioterapia intraperitoneale ipertermica per carcinosi peritoneale da carcinoma ovarico (2017)</li> <li>○ Co-author of Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018)</li> <li>○ Co-chair and co-author of the GCIG VI World Consensus Conference on the Treatment of Ovarian Cancer and Clinical Research (2020)</li> <li>○ From 2018 coordinator and co-author of the national guidelines (AIOM) on treatment of ovarian cancer</li> <li>○ Chair and co-author of the Italian Consensus Conference on the management of uterine sarcomas (2019)</li> <li>○ Co-author of the 1st edition GCIG-ESGO guidelines on the treatment of rare gynecological cancers (2019)</li> <li>○ Co-author of "ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2016)</li> <li>○ Co-author of "AIOM recommendations for implementation of the BRCA test in patients with ovarian cancer and in their families" (2019)</li> <li>○ Co-author of "AIOM recommendations for the implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies" (2022)</li> <li>○ Coordinator and co-author of "AIOM recommendations for implementation of the MSI test in patients with endometrial cancer" (2022)</li> <li>○ Co-author of ESMO clinical practice guidelines on Endometrial Cancer Treatment (2022)</li> <li>○ Co-author of PAN-ASIAN Adaptation of ESMO clinical practice guidelines on Endometrial Cancer Treatment (2022)</li> <li>○ Co-author of "European experts consensus on BRCA/homologous recombination deficiency testing in first-line ovarian cancer (2022)</li> <li>○ Co-author of ESMO ESGO Clinical Practice Guideline for diagnosis, treatment and follow-up of patients with epithelial ovarian cancer (2023)</li> <li>○ Co-author of ESGO-ESTRO-ESP guidelines on Cervical Cancer Treatment (2023)</li> <li>○ Working group Chair and co-author of "ESMO-ESGO-ESP Consensus Conference on Ovarian Cancer" (2023)</li> </ul>
--	---

#### Participation in Congresses

Invited speaker and/or scientific coordinator of several (around 300 from 2008) national and international scientific meetings

#### Grant, Co-funded projects, Awards and Honors

- GCIG 2016 Merit Awards for Endometrial Working Group Chair
- INC Research 2016 Clinical Research Site Award
- 2021 "Adele Leone memory" ACTO prize for Ovarian Cancer Treatment merit
- ESGO 2017: Best oral presentation for "The Lyon study: Randomized phase 3 trial on the role of lymphadenectomy in Ovarian Cancer"
- AIRC 2008: sub-investigator/scientific collaborator for the project: "Carbo/taxol vs carbo/lip doxorubicin in ovarian cancer: molecular factors in the MITO 2 trial tissue bank"
- AIRC 2012: sub-investigator/scientific collaborator for the project: "Carbo/taxol weekly vs 3-weekly in advanced ovarian cancer: molecular factors in the MITO 7 trial molecular tissue bank"
- AIRC 2012: sub-investigator/scientific collaborator for the project: "The ovarian cancer cholinic phenotype: exploring possible theragnostic window"
- Fondazione Cariplo 2013: sub-investigator/scientific collaborator for the project: "Disease recurrence in epithelial ovarian cancer: deciphering mRNA-driven regulatory networks related to drug sensitivity/cellular plasticity and exploring nanomaterial based targeted delivery of identified key molecules for therapeutic purposes"
- Fondazione Cariplo 2013: sub-investigator/scientific collaborator for the project: "Role of tumor microenvironment in thyroid carcinogenesis onset and progression: thyroid cells cross-talk with macrophages"
- AIRC 2013: sub-investigator/scientific collaborator for the project: "Metabolic effects of anti-angiogenic therapy in cancer and their therapeutic implications"
- AIRC 2015: sub-investigator/scientific collaborator for the project: "Integrated genomics, epigenomics and metabolic approach to overcome ovarian cancer early relapse and chemoresistance"
- AIRC 2016: Principal Investigator for the project: "Bevacizumab in ovarian cancer: identification of molecular signature driving patients selection"
- 2018: Principal Investigator and Italian coordinator of the European project GANNET53 (FP7) for the EUDARIO study: "European Trial on DNA Repair inhibition in ovarian cancer"
- 2019: "Bando ricerca finalizzata ministero della Salute". Principal investigator of the project: "Parp Inhibitors In First Line Ovarian Cancer Treatment: Prediction Of Response And Resistance"
- AIRC 2021 **Principal investigator** of the project "Predictive biomarkers of response in PARP+immune checkpoint inhibitors combination in recurrent ovarian cancer"
- Principal Investigator of the following co-funded academic trials:
  - Randomized phase III trial on Trabectedin (ET-743) vs clinician's choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAneSS phenotype patients MITO-23 Co-funded by Pharma-mar;
  - Phase II trial on Trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (CS) MITO 26 Co-funded by Pharma-mar;
  - Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer: MITO CERV 3 trial. Co-funded by MSD;

	<ul style="list-style-type: none"> <li>- Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and cervical lesions. MITO CERV 4 trial. Co-funded by MSD;</li> <li>- Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS &gt;1 positive ovarian, Fallopian tube and primary peritoneal cancer patients. MITO 27 trial: Co-funded by MSD;</li> <li>- Randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination. MITO 25.1 trial. Co-funded by Clovis Oncology;</li> <li>- Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) vs physician's choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment. ENGOT-ov51/NItCHE/MITO 33 Co-funded by GSK;</li> <li>- Niraparib as maintenance treatment in platinum responsive ovarian cancer patients: a real life study by MITO group. MITO 34 trial: Co-funded by GSK.</li> </ul>
--	---

	<p><u>Books or books chapters:</u></p> <ul style="list-style-type: none"> <li>○ Lorusso D, D'Agostino G, Ferrandina G, Scambia G. <i>Tumori dell'apparato genitale femminile</i>. In: Santoro A: Terapia medica oncologica. Edises 2001</li> <li>○ Lorusso D, Gallotta V, Scambia G. <i>Il carcinoma dell'ovaio</i>. In "Manuale di Oncologia Medica", Momento Medico 2003</li> <li>○ Lorusso D, Pietragalla A, Mainenti S, Scambia G. <i>Tumori dell'ovaio</i> In: Lopez: Oncologia medica pratica. SEU 2010</li> <li>○ Manuale Utet "Tumori ginecologici" Lorusso D, Pietragalla A, Mainenti S, Di Legge A, Amadio G, Scambia G.</li> <li>○ <i>Il carcinoma epiteliale dell'ovaio: diagnosi, prognosi e trattamento</i>. Lorusso D, Pietragalla A, Scambia G. Edizioni Internazionali CIC, Nov 2010</li> <li>○ "Tumori della vulva e della vagina" in <i>La medicina oncologica</i>. La Bianca, Cascinu. Ed Edra 2013</li> <li>○ De Vita "Medicina oncologica" writing in Italian of the chapters concerning oncological gynecology and trophoblast diseases. Piccin Editore ed 2017</li> <li>○ From 2013 to 2023 Author of annual editions of the AIOM-AIRTUM Manual "I numeri del cancro in italia" for the chapter "I tumori dell'utero e i sarcomi"</li> <li>○ Lorusso D and Mirza MR. Chemotherapy in endometrial cancer. In: Management of endometrial cancer. Editor: Mirza MR; 2019; pp. 231-242 Springer Nature, ISBN 978-3-319-64512-4</li> <li>○ Lorusso D and Tripodi E "Role of immunotherapy in endometrial and cervical cancer" in ESMO Handtbook of immuno-oncology, 2018</li> <li>○ Lorusso D. "The treatment of ovarian cancer". Edizioni Minerva Medica 2022</li> </ul>
<b>TECHNICAL SKILLS AND COMPETENCES ACQUIRED IN THE COURSE OF LIFE AND CAREER</b>	Highly experienced in medical treatment of gynecological neoplasms and in the design, conduction, and management of phase I-IV clinical trials, according to the GCP. Principal investigator (108 studies in the last 10 years) and Co-investigator of several phase I-IV studies in the field of medical and surgical treatment of gynecological cancers.

MOTHER TONGUE	Italian
---------------	---------

OTHER LANGUAGES	English
• Reading skills	Excellent

• Writing skills	Excellent
• Verbal skills	Excellent

ORGANISATIONAL SKILLS AND COMPETENCES	Good Relationship Capabilities with oncologic patients and their familiars Good Relationship and Communication Capabilities with colleagues inside the hospital Great networking capabilities with physicians outside the hospital Organizational skills in clinical and research field Great capability of personnel management Great interactions with different stakeholders (pharmaceutical companies, patients advocacy groups, charity organizations etc)
---------------------------------------	--

ANNEXES	Author of 354 papers on peer reviewed journals H-Index 48 (Scopus) H-Index from 2019 to 2023: 23 (Scopus) SCOPUS AUTHOR ID: 7006768603 ORCID ID: 0000-0003-0981-0598 RESEARCH ID: k-6523-2016
---------	--

Research interest:

Dr Lorusso has been involved in gynaecological oncology research since more than 20 years and has conducted approximately 108 phase I-IV clinical trials in gynaecological malignancies in the last 10 years. At present she is Principal Investigators of 30 active studies. Dr Lorusso is responsible of the Clinical Trials Committee of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies) Group, which includes more than 180 Italian centres involved in gynaecological oncology research. She is member of Board of Directors of Gynaecological Cancer Intergroup which includes 23 international research groups promoting and conducting high quality, practice changing clinical trials to improve the outcome for women with gynaecological cancers. She is ESGO (European Society of Gynecological Oncology) Council Member, deeply involved into the promotion of the health and well-being of women with gynaecological cancers through **prevention, research, excellence in care and education**. Dr Lorusso is also active member of ENGOT (European Network of Gynaecological Oncological Trial groups) an international organisation which coordinates and promotes clinical trials within Europe for patients with gynaecological cancers. She chairs the Gynecological Cancer Accademy (GCA), an organization created to promote networking and mentorship of the future leaders in the treatment of gynecologic cancers in Europe. She has also co-authored more than 354 oncology publications on peer reviewed journals. She is author of national and international guidelines on treatment of ovarian, cervical, endometrial, vulvar cancer and rare gynecologic tumors. Dr Lorusso's key goals are to promote clinical research, international and national collaboration and patients and clinicians' education and to ameliorate global treatment of gynaecological malignancies.

- "La sottoscritta, consapevole che – ai sensi dell'art. 76 del D.P.R. 445/2000 – le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni rispondono a verità"

- "Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base al D. Lgs. 196/2003, coordinato con il D. Lgs. 101/2018, e al Regolamento UE 2016/679"

12/12/2025

Signature

Domenica Lorusso

